Home LiteratureArticle Details
PMID: 19127586 Published · ppublish English Journal Article Review

What causes cell death in Parkinson's disease?

Annals of neurology ·Vol. 64 Suppl 2 ·2008-12-00 ·Pages S3-15

Gupta A, Dawson VL, Dawson TM

Abstract

Currently, there is no proven neuroprotective or neurorestorative therapy for Parkinson's disease (PD). Several advances in the genetics of PD have created an opportunity to develop mechanistic-based therapies that hold particular promise for identifying agents that slow and even halt the progression of PD, as well as restore function. Here we review many of the advances in the last decade regarding the identification of new targets for the treatment of PD based on understanding the molecular mechanisms of how mutations in genes linked to PD cause neurodegeneration.

MeSH Terms
Animals Cell Death/genetics,physiology Humans Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Mutation Neuroprotective Agents/therapeutic use Parkinson Disease/genetics,pathology,physiopathology,therapy Protein Serine-Threonine Kinases/genetics alpha-Synuclein/genetics
Chemicals
Neuroprotective Agents alpha-Synuclein LRRK2 protein, human Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Protein Serine-Threonine Kinases
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Gupta Amitabh
Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Dawson Valina L
Dawson Ted M
References (119)
119 references, click to expand
  1. Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery.
    Neuron. 2006 Oct 5;52(1):33-8 PMID: 17015225
  2. Association of the cytoskeletal GTP-binding protein Sept4/H5 with cytoplasmic inclusions found in Parkinson's disease and other synucleinopathies.
    J Biol Chem. 2003 Jun 27;278(26):24095-102 PMID: 12695511
  3. Neuroprotection and dopamine agonists.
    Neurology. 2002 Feb 26;58(4 Suppl 1):S9-18 PMID: 11909981
  4. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy.
    Science. 2004 Aug 27;305(5688):1292-5 PMID: 15333840
  5. Silencing of human alpha-synuclein in vitro and in rat brain using lentiviral-mediated RNAi.
    Exp Neurol. 2006 Apr;198(2):382-90 PMID: 16455076
  6. Neuroprotective and neurorestorative strategies for Parkinson's disease.
    Nat Neurosci. 2002 Nov;5 Suppl:1058-61 PMID: 12403986
  7. Autophagy and neurodegeneration: when the cleaning crew goes on strike.
    Lancet Neurol. 2007 Apr;6(4):352-61 PMID: 17362839
  8. HDAC6 and microtubules are required for autophagic degradation of aggregated huntingtin.
    J Biol Chem. 2005 Dec 2;280(48):40282-92 PMID: 16192271
  9. Are ubiquitination pathways central to Parkinson's disease?
    Cell. 2003 Jul 11;114(1):1-8 PMID: 12859888
  10. Cell systems and the toxic mechanism(s) of alpha-synuclein.
    Exp Neurol. 2008 Jan;209(1):5-11 PMID: 17603039
  11. Early-onset familial parkinsonism due to POLG mutations.
    Ann Neurol. 2006 May;59(5):859-62 PMID: 16634032
  12. Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP.
    Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14524-9 PMID: 12376616
  13. Molecular pathways of neurodegeneration in Parkinson's disease.
    Science. 2003 Oct 31;302(5646):819-22 PMID: 14593166
  14. Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions.
    Nat Genet. 1999 May;22(1):110-4 PMID: 10319874
  15. Rotigotine treatment partially protects from MPTP toxicity in a progressive macaque model of Parkinson's disease.
    Exp Neurol. 2007 Feb;203(2):415-22 PMID: 17045989
  16. Dynamics of alpha-synuclein aggregation and inhibition of pore-like oligomer development by beta-synuclein.
    FEBS J. 2007 Apr;274(7):1862-77 PMID: 17381514
  17. Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration.
    Cell. 2005 Nov 4;123(3):383-96 PMID: 16269331
  18. The chaperone activity of heat shock protein 90 is critical for maintaining the stability of leucine-rich repeat kinase 2.
    J Neurosci. 2008 Mar 26;28(13):3384-91 PMID: 18367605
  19. Linking SIRT2 to Parkinson's disease.
    ACS Chem Biol. 2007 Aug 17;2(8):529-32 PMID: 17708669
  20. HtrA2 and Parkinson's disease: think PINK?
    Nat Cell Biol. 2007 Nov;9(11):1227-9 PMID: 17975547
  21. Parkin functions as an E2-dependent ubiquitin- protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1.
    Proc Natl Acad Sci U S A. 2000 Nov 21;97(24):13354-9 PMID: 11078524
  22. Role of voltage-gated L-type Ca2+ channel isoforms for brain function.
    Biochem Soc Trans. 2006 Nov;34(Pt 5):903-9 PMID: 17052224
  23. PINK1 protects against oxidative stress by phosphorylating mitochondrial chaperone TRAP1.
    PLoS Biol. 2007 Jul;5(7):e172 PMID: 17579517
  24. S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function.
    Science. 2004 May 28;304(5675):1328-31 PMID: 15105460
  25. DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase.
    Proc Natl Acad Sci U S A. 2007 Sep 11;104(37):14807-12 PMID: 17766438
  26. alpha-Synuclein and Parkinson disease susceptibility.
    Neurology. 2007 Oct 30;69(18):1745-50 PMID: 17872362
  27. Identification of far upstream element-binding protein-1 as an authentic Parkin substrate.
    J Biol Chem. 2006 Jun 16;281(24):16193-6 PMID: 16672220
  28. Rifampicin protects PC12 cells against MPP+-induced apoptosis and inhibits the expression of an alpha-Synuclein multimer.
    Brain Res. 2007 Mar 30;1139:220-5 PMID: 17280646
  29. Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease.
    Neuron. 2005 Jun 16;46(6):857-68 PMID: 15953415
  30. Creatine and cyclocreatine attenuate MPTP neurotoxicity.
    Exp Neurol. 1999 May;157(1):142-9 PMID: 10222117
  31. Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease.
    Hum Mol Genet. 2005 Aug 1;14(15):2099-111 PMID: 15961413
  32. Tyrosine kinases as therapeutic targets in BCR-ABL negative chronic myeloproliferative disorders.
    Curr Drug Targets. 2007 Feb;8(2):205-16 PMID: 17305499
  33. Localization of LRRK2 to membranous and vesicular structures in mammalian brain.
    Ann Neurol. 2006 Nov;60(5):557-69 PMID: 17120249
  34. Future directions in the treatment of Parkinson's disease.
    Mov Disord. 2007 Sep;22 Suppl 17:S385-91 PMID: 18175401
  35. Accumulation of the authentic parkin substrate aminoacyl-tRNA synthetase cofactor, p38/JTV-1, leads to catecholaminergic cell death.
    J Neurosci. 2005 Aug 31;25(35):7968-78 PMID: 16135753
  36. Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases.
    Neuron. 2001 Jan;29(1):15-32 PMID: 11182078
  37. Kinase activity of mutant LRRK2 mediates neuronal toxicity.
    Nat Neurosci. 2006 Oct;9(10):1231-3 PMID: 16980962
  38. Parkin blushed by PINK1.
    Neuron. 2006 May 18;50(4):527-9 PMID: 16701203
  39. Sept4, a component of presynaptic scaffold and Lewy bodies, is required for the suppression of alpha-synuclein neurotoxicity.
    Neuron. 2007 Feb 15;53(4):519-33 PMID: 17296554
  40. Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial Parkinsonism-linked gene DJ-1.
    Neuron. 2005 Feb 17;45(4):489-96 PMID: 15721235
  41. Pink1, Parkin, DJ-1 and mitochondrial dysfunction in Parkinson's disease.
    Curr Opin Neurobiol. 2007 Jun;17(3):331-7 PMID: 17499497
  42. The familial Parkinsonism gene LRRK2 regulates neurite process morphology.
    Neuron. 2006 Nov 22;52(4):587-93 PMID: 17114044
  43. Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases.
    Proc Natl Acad Sci U S A. 2006 Mar 14;103(11):4246-51 PMID: 16537516
  44. Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease.
    Science. 2007 Jul 27;317(5837):516-9 PMID: 17588900
  45. DJ-1 transcriptionally up-regulates the human tyrosine hydroxylase by inhibiting the sumoylation of pyrimidine tract-binding protein-associated splicing factor.
    J Biol Chem. 2006 Jul 28;281(30):20940-20948 PMID: 16731528
  46. Alpha-synuclein and neurodegenerative diseases.
    Nat Rev Neurosci. 2001 Jul;2(7):492-501 PMID: 11433374
  47. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase.
    Nat Genet. 2006 Oct;38(10):1184-91 PMID: 16964263
  48. Interaction of DJ-1 with Daxx inhibits apoptosis signal-regulating kinase 1 activity and cell death.
    Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9691-6 PMID: 15983381
  49. Parkinson's disease.
    Hum Mol Genet. 2007 Oct 15;16 Spec No. 2:R183-94 PMID: 17911161
  50. Lrrk2 in the limelight!
    Neurology. 2007 Oct 30;69(18):1732-3 PMID: 17967990
  51. Neuroprotective role of the Reaper-related serine protease HtrA2/Omi revealed by targeted deletion in mice.
    Mol Cell Biol. 2004 Nov;24(22):9848-62 PMID: 15509788
  52. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system.
    Neuron. 2000 Jan;25(1):239-52 PMID: 10707987
  53. RNA interference-mediated knockdown of alpha-synuclein protects human dopaminergic neuroblastoma cells from MPP(+) toxicity and reduces dopamine transport.
    J Neurosci Res. 2007 Feb 1;85(2):351-63 PMID: 17131421
  54. Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models.
    Science. 2006 Jul 21;313(5785):324-8 PMID: 16794039
  55. A regulated interaction with the UIM protein Eps15 implicates parkin in EGF receptor trafficking and PI(3)K-Akt signalling.
    Nat Cell Biol. 2006 Aug;8(8):834-42 PMID: 16862145
  56. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin.
    Nature. 2006 Jun 29;441(7097):1162-6 PMID: 16672981
  57. Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase.
    Proc Natl Acad Sci U S A. 2008 Feb 5;105(5):1499-504 PMID: 18230735
  58. Mitochondrial DNA polymerase gamma variants in idiopathic sporadic Parkinson disease.
    Neurology. 2007 Sep 11;69(11):1152-9 PMID: 17846414
  59. Inhibitors of alpha-synuclein oligomerization and toxicity: a future therapeutic strategy for Parkinson's disease and related disorders.
    Exp Brain Res. 2006 Aug;173(2):223-33 PMID: 16733698
  60. Identification of novel proteins associated with both alpha-synuclein and DJ-1.
    Mol Cell Proteomics. 2007 May;6(5):845-59 PMID: 16854843
  61. Parkinson's disease and dementia with Lewy bodies: a difference in dose?
    Lancet. 2004 Sep 25-Oct 1;364(9440):1105-7 PMID: 15451205
  62. Loss of Omi mitochondrial protease activity causes the neuromuscular disorder of mnd2 mutant mice.
    Nature. 2003 Oct 16;425(6959):721-7 PMID: 14534547
  63. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin.
    Nature. 2006 Jun 29;441(7097):1157-61 PMID: 16672980
  64. Targeting alpha-synuclein in Parkinson's disease.
    Chem Biol. 2004 Nov;11(11):1476-8 PMID: 15555995
  65. Mitochondrial dysfunction in Parkinson's disease.
    Cell Death Differ. 2007 Jul;14(7):1261-6 PMID: 17464321
  66. Parkinson's disease: return of an old prime suspect.
    Neuron. 2007 Jul 5;55(1):8-10 PMID: 17610813
  67. Nitrated alpha-synuclein immunity accelerates degeneration of nigral dopaminergic neurons.
    PLoS One. 2008 Jan 02;3(1):e1376 PMID: 18167537
  68. Loss-of-function of human PINK1 results in mitochondrial pathology and can be rescued by parkin.
    J Neurosci. 2007 Nov 7;27(45):12413-8 PMID: 17989306
  69. Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration.
    Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18676-81 PMID: 16352719
  70. Parkin-associated Parkinson's disease.
    Cell Tissue Res. 2004 Oct;318(1):175-84 PMID: 15503153
  71. The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity.
    Hum Mol Genet. 2006 Jan 15;15(2):223-32 PMID: 16321986
  72. Mutation of the linker region of the polymerase gamma-1 (POLG1) gene associated with progressive external ophthalmoplegia and Parkinsonism.
    Arch Neurol. 2007 Apr;64(4):553-7 PMID: 17420318
  73. Dominant inheritance of premature ovarian failure associated with mutant mitochondrial DNA polymerase gamma.
    Hum Reprod. 2006 Oct;21(10):2467-73 PMID: 16595552
  74. Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease.
    Nat Med. 2001 Oct;7(10):1144-50 PMID: 11590439
  75. The kinase domain of mitochondrial PINK1 faces the cytoplasm.
    Proc Natl Acad Sci U S A. 2008 Aug 19;105(33):12022-7 PMID: 18687899
  76. DJ-1, a cancer- and Parkinson's disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2.
    Proc Natl Acad Sci U S A. 2006 Oct 10;103(41):15091-6 PMID: 17015834
  77. Anti-fibrillogenic and fibril-destabilizing activities of anti-Parkinsonian agents for alpha-synuclein fibrils in vitro.
    J Neurosci Res. 2007 May 15;85(7):1547-57 PMID: 17387689
  78. Nitrosative stress linked to sporadic Parkinson's disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity.
    Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10810-4 PMID: 15252205
  79. BAG5 inhibits parkin and enhances dopaminergic neuron degeneration.
    Neuron. 2004 Dec 16;44(6):931-45 PMID: 15603737
  80. Calcium, ageing, and neuronal vulnerability in Parkinson's disease.
    Lancet Neurol. 2007 Oct;6(10):933-8 PMID: 17884683
  81. Plasma membrane ion permeability induced by mutant alpha-synuclein contributes to the degeneration of neural cells.
    J Neurochem. 2006 May;97(4):1071-7 PMID: 16606366
  82. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism.
    Nature. 1998 Apr 9;392(6676):605-8 PMID: 9560156
  83. GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease.
    Biochemistry. 2007 Feb 6;46(5):1380-8 PMID: 17260967
  84. Morphology and electrophysiological properties of immunocytochemically identified rat dopamine neurons recorded in vitro.
    J Neurosci. 1989 Oct;9(10):3463-81 PMID: 2795134
  85. Excitotoxicity and nitric oxide in Parkinson's disease pathogenesis.
    Ann Neurol. 1998 Sep;44(3 Suppl 1):S110-4 PMID: 9749581
  86. PARK9-linked parkinsonism in eastern Asia: mutation detection in ATP13A2 and clinical phenotype.
    Neurology. 2008 Apr 15;70(16 Pt 2):1491-3 PMID: 18413573
  87. Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations.
    Proc Natl Acad Sci U S A. 2005 Feb 8;102(6):2162-7 PMID: 15684072
  88. Role of dopamine agonists in Parkinson's disease: an update.
    Expert Rev Neurother. 2007 Oct;7(10):1391-9 PMID: 17939774
  89. Clearance of alpha-synuclein oligomeric intermediates via the lysosomal degradation pathway.
    J Neurosci. 2004 Feb 25;24(8):1888-96 PMID: 14985429
  90. Resveratrol protects dopaminergic neurons in midbrain slice culture from multiple insults.
    Biochem Pharmacol. 2007 Feb 15;73(4):550-60 PMID: 17147953
  91. Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity.
    Hum Mol Genet. 2007 Jan 15;16(2):223-32 PMID: 17200152
  92. ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease.
    Neurology. 2007 May 8;68(19):1557-62 PMID: 17485642
  93. Failure of the ubiquitin-proteasome system in Parkinson's disease.
    Nat Rev Neurosci. 2001 Aug;2(8):589-94 PMID: 11484002
  94. Parkinson's disease, pesticides and mitochondrial dysfunction.
    Trends Neurosci. 2001 May;24(5):245-7 PMID: 11311359
  95. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity.
    Proc Natl Acad Sci U S A. 2005 Nov 15;102(46):16842-7 PMID: 16269541
  96. Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants.
    J Neurochem. 2007 Oct;103(1):238-47 PMID: 17623048
  97. Hereditary early-onset Parkinson's disease caused by mutations in PINK1.
    Science. 2004 May 21;304(5674):1158-60 PMID: 15087508
  98. CHIP is associated with Parkin, a gene responsible for familial Parkinson's disease, and enhances its ubiquitin ligase activity.
    Mol Cell. 2002 Jul;10(1):55-67 PMID: 12150907
  99. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease.
    Science. 2002 Feb 1;295(5556):865-8 PMID: 11823645
  100. Neuroprotection by pharmacologic blockade of the GAPDH death cascade.
    Proc Natl Acad Sci U S A. 2006 Mar 7;103(10):3887-9 PMID: 16505364
  101. Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity.
    J Biol Chem. 2000 Nov 17;275(46):35661-4 PMID: 10973942
  102. Kinase activity is required for the toxic effects of mutant LRRK2/dardarin.
    Neurobiol Dis. 2006 Aug;23(2):329-41 PMID: 16750377
  103. Medicine. The yin-yang of sirtuins.
    Science. 2007 Jul 27;317(5837):461-2 PMID: 17656709
  104. The R1441C mutation of LRRK2 disrupts GTP hydrolysis.
    Biochem Biophys Res Commun. 2007 Jun 8;357(3):668-71 PMID: 17442267
  105. Update on the genetics of Parkinson's disease.
    Mov Disord. 2007 Sep;22 Suppl 17:S343-50 PMID: 18175395
  106. Genetic variability in the SNCA gene influences alpha-synuclein levels in the blood and brain.
    FASEB J. 2008 May;22(5):1327-34 PMID: 18162487
  107. Targeting programmed cell death in neurodegenerative diseases.
    Nat Rev Neurosci. 2003 May;4(5):365-75 PMID: 12728264
  108. Pharmacological prevention of Parkinson disease in Drosophila.
    Nat Med. 2002 Nov;8(11):1185-6 PMID: 12411925
  109. Coenzyme Q10 as a possible treatment for neurodegenerative diseases.
    Free Radic Res. 2002 Apr;36(4):455-60 PMID: 12069110
  110. 'Rejuvenation' protects neurons in mouse models of Parkinson's disease.
    Nature. 2007 Jun 28;447(7148):1081-6 PMID: 17558391
  111. An antiaggregation gene therapy strategy for Lewy body disease utilizing beta-synuclein lentivirus in a transgenic model.
    Gene Ther. 2004 Dec;11(23):1713-23 PMID: 15483670
  112. The molecular biology of mammalian SIRT proteins: SIRT2 in cell cycle regulation.
    Cell Cycle. 2007 May 2;6(9):1011-8 PMID: 17457050
  113. Rifampicin inhibits alpha-synuclein fibrillation and disaggregates fibrils.
    Chem Biol. 2004 Nov;11(11):1513-21 PMID: 15556002
  114. The mitochondrial protease HtrA2 is regulated by Parkinson's disease-associated kinase PINK1.
    Nat Cell Biol. 2007 Nov;9(11):1243-52 PMID: 17906618
  115. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase.
    Nat Genet. 2000 Jul;25(3):302-5 PMID: 10888878
  116. Inclusion body formation and neurodegeneration are parkin independent in a mouse model of alpha-synucleinopathy.
    J Neurosci. 2006 Apr 5;26(14):3685-96 PMID: 16597723
  117. Chronic systemic pesticide exposure reproduces features of Parkinson's disease.
    Nat Neurosci. 2000 Dec;3(12):1301-6 PMID: 11100151
  118. LRRK2 mutation analysis in Parkinson disease families with evidence of linkage to PARK8.
    Neurology. 2007 Oct 30;69(18):1737-44 PMID: 17804834
  119. LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity.
    Biochem J. 2007 Jul 15;405(2):307-17 PMID: 17447891
Article Info
Journal
Annals of neurology
Abbr.
Ann Neurol
ISSN
1531-8249
DOI
10.1002/ana.21573
Published
2008-12-00
Pages
S3-15
Language
English
Region
United States
NLM ID
7707449
PMCID
PMC4118469
Subset
IM
Grants
NINDS NIH HHS · P50 NS038377 · United States
NINDS NIH HHS · R01 NS048206 · United States
External Links
PubMed source DOI: 10.1002/ana.21573 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2